Skip to main content

Day: August 23, 2021

Investeringsforeningen Great Dane – Halvårsrapport 2021

Bestyrelsen for Investeringsforeningen Great Dane har i dag den 23. august 2021 godkendt foreningens halvårsrapport for 2021. Rapporten, der ikke er revideret, er vedhæftet denne meddelelse. Halvårsrapporten kan endvidere downloades fra foreningens hjemmeside www.greatdanefund.dk samt rekvireres ved henvendelse til Invest Administration A/S, Badstuestræde 20, 1209 København K, tlf. 3814 6600. Med venlig hilsen Bestyrelsenfor Investeringsforeningen Great DaneAttachmentGreat Dane – Halvårsrapport 2021

Continue reading

Orphazyme announces publication of results from its Phase 2/3 trial of arimoclomol in Niemann-Pick disease type C in the Journal of Inherited Metabolic Disease

Orphazyme A/SInvestor newsNo. 07/2021Company Registration No. 32266355Arimoclomol was well–tolerated with a statistically significant and clinically meaningful effect on disease progressionCopenhagen – August 23, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announced that results from a Phase 2/3 trial of arimoclomol, an investigational heat-shock protein amplifier, in Niemann-Pick disease type C (NPC) have been published in the peer-reviewed Journal of Inherited Metabolic Disease (JIMD). The online publication is available here. “We are pleased to share the data from our Phase 2/3 trial in JIMD. NPC is a rare, inherited progressive neurodegenerative disorder with a high unmet medical need for disease-modifying treatment options. This trial demonstrated a statistically significant and...

Continue reading

Autonomous Cars Market to Reach USD 11.03 Billion by 2028, with 31.3% CAGR; Rapid Development of Sensor-processing Technologies to Boost Growth, says Fortune Business Insights™

Top Players Covered in the Autonomous Cars Market Research Report are Autoliv Inc. (Stockholm, Sweden), Aptiv (Dublin, Ireland), Waymo LLC ( California, United States), Robert Bosch GmbH ( Gerlingen, Germany), Daimler AG ( Stuttgart, Germany), Baidu (Beijing, China), AutoX, Inc. (California, United States), Pony.ai (Fremont, California, United States), Ford Motor Company (Michigan, United States), HYUNDAI MOTOR GROUP (Seoul, South Korea), Volvo (Gothenburg, Sweden) and other players Pune, India, Aug. 23, 2021 (GLOBE NEWSWIRE) — The global autonomous cars market size was USD 1.45 billion in 2020. The market is projected to grow from USD 1.64 billion in 2021 to USD 11.03 billion in 2028 at a CAGR of 31.3% in the 2021-2028 period. This information is provided by Fortune Business Insights™ in its report titled, “Autonomous Cars...

Continue reading

Blood Pressure Monitors Market to Reach USD 3.21 Billion with 9.8% CAGR by 2028; Increasing Development of Technologically Advanced Devices to Aid Growth: Fortune Business Insights™

Top Players Covered in the Blood Pressure Monitors Market Research Report Are Omron Healthcare, Inc. (Kyoto, Japan), Hill-Rom Holdings, Inc. (Indiana, United States), Nihon Kohden Corporation (Tokyo, Japan), Koninklijke Philips N.V. (Amsterdam, Netherlands), Masimo (Irvine, California), Beurer GmbH (Ulm, Germany), GE Healthcare (General Electric Company) (Chicago, United States), American Diagnostic Corporation (Sweden, Europe), SunTech Medical, Inc. (Morrisville, United States) and other key market players. Pune, India, Aug. 23, 2021 (GLOBE NEWSWIRE) — The global blood pressure monitors market is set to gain traction from the increasing shift of patients from hospital care to home care devices because of the ongoing COVID-19 pandemic. Renowned companies, such as Omron Healthcare, Inc. are persistently striving to launch technologically...

Continue reading

US Dialysis Services Market to Reach USD 32.46 Billion by 2028; Surging Technological Advances in Telehealth to Bolster Growth: Fortune Business Insights™

Key Companies covered in the Dialysis Services Market Research Report are: Fresenius Medical Care AG & Co. (Bad Homburg, Germany), DaVita Inc. (Denver, Colorado, United States), American Renal® Associates (Beverly, Massachusetts, United States), U.S. Renal Care, Inc.( Plano, Texas, United States), Satellite Healthcare (San Jose, United States), Baxter (Illinois, United States), B. Braun Melsungen AG, (Melsungen, Germany), Becton, Dickinson and Company (New Jersey, United States), DCI Inc. (Tennessee, United States), NxStage Medical, Inc. (Massachusetts, United States) Pune, India, Aug. 23, 2021 (GLOBE NEWSWIRE) — The US Dialysis Services Market size was USD 25.87 billion in 2020. The market is expected to grow from USD 26.20 billion in 2021 to USD 32.46 billion in 2028 at a CAGR of 3.11% in the 2021-2028 period. This information...

Continue reading

A letter of intent was signed to align EQ Labs, Inc. (EQLB) and KANGE CORP. (KGNR)

Las Vegas, NV, Aug. 23, 2021 (GLOBE NEWSWIRE) — A letter of intent was signed to align EQ Labs, Inc. (OTC Pink: EQLB) and KANGE CORP. (KGNR) to explore the possibility of an acquisition that will strengthen the position and placement of Last Shot® in the marketplace. “We’ve looked at all of our options that could possibly benefit the Last Shot ® brand.  We also considered what would bring value to shareholders, and support our business model.  We are excited that our new potential alignment with KANGE CORP. (KGNR) will meet and exceed all of our expectations” said Mo Owens, EQ Labs Inc. CEO and Founder. Please look for additional announcements in the coming weeks as developments continue. We as a company feel that we should explore all viable options going forward that is in the best interest of our shareholders, especially as...

Continue reading

Prosafe SE: Finalization of conversion of convertible bonds – issue of shares

Reference is made to press release Update on financial process – Conversion of convertible bonds on 6 August 2021. Finalization of the conversion has been carried out today. Reference is made to the convertible bonds issued by Prosafe SE (“Prosafe” or the “Company”) on 15 September 2016, with ISIN NO 0010771025. Convertible Bonds of nominal value NOK 35,706,341 have today been converted into 1,428,253 new ordinary shares in the Company, based on the conversion price of NOK 25 per share. Following the conversion, the remaining outstanding principal of the Convertible Bonds is reduced to zero. Reference is made to the convertible bonds issued by Prosafe on 16 December 2016, with ISIN NO 001 0781008. Convertible Bonds of nominal value NOK 122,836,000 have today been converted into 4,094,533 new ordinary shares in...

Continue reading

Coloplast A/S – Transactions in connection with share buy-back programme, week 33 (programme completed)

As mentioned in Announcement no. 02/2021 Coloplast is initiating a share buyback programme totalling up to DKK 500 million. The share buyback programme was carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations with the purpose of meeting obligations arising from share options programmes or other allocation of shares to employees or to complete a share capital decrease as set out in Articles 5(2)(a) and 5(2)(c) in MAR. The following transactions have been executed during the period 16 – 20 August 2021:Date Number of shares Average purchase price, DKK Transaction value, DKK16 August 2021  3,000  1,135.37  3,406,11017 August 2021  5,000  1,140.37  5,701,850...

Continue reading

PCI Biotech: Invitation to first half-year 2021 result presentation

Oslo, Norway, 23 August 2021 – PCI Biotech’s (OSE: PCIB) first half-year 2021 interim report will be released on 31 August 2021 at 07.00 CEST. The interim report and presentation will be made available on www.newsweb.no and on the company’s webpage, www.pcibiotech.com. A results presentation (in English) will be held through a live webcast at 08.30 CEST the same day. The webcast can be accessed through www.pcibiotech.com. There will be a Q&A session at the end of the presentation. It will be possible to post written questions through the webcast console or through a teleconference facilitated for investors intending to ask questions verbally during the Q&A session. For further information, please contact:Ronny Skuggedal, CFOEmail: rs@pcibiotech.noMobile: +47 9400 5757 About PCI Biotech        PCI Biotech is a biopharmaceutical...

Continue reading

Nexstim Announces Continuation of Pilot Study in Treatment of Severe Depression at Kuopio University Hospital

Company Announcement, Inside information, Helsinki, 23 August 2021 at 10:45 AM (EEST) Nexstim Announces Continuation of Pilot Study in Treatment of Severe Depression at Kuopio University Hospital Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “Company”) announces the continuation of the pilot study on the use of accelerated iTBS protocol in treatment of severe depression with Nexstim NBT® System at Kuopio University Hospital. The start of the pilot study was first announced on 22 September 2020. Accelerated iTBS means transcranial magnetic stimulation (TMS) therapy where stimulation is given several times per day for one week whereas in conventional TMS therapy, stimulation is given once a day during several weeks. In the continuation of the previously reported pilot study, the effectiveness of the accelerated...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.